MacroGenics MGNX 深 滬
等待開盤 08-26 09:30:00 美东时间
1.655
-0.035
-2.07%
華盛通- 最 高1.79
- 今 開1.72
- 成交量 80.47万股
- 最 低 1.65
- 昨 收 1.69
- 總市值 1.04亿
- 52周最高 5.10
- 市盈率 靜 --
- 換手率 1.28%
- 52周最低 0.9897
- 委 比 36.67%
- 總股本 6309.03万
- 歷史最高 41.00
- 量 比 1.26
- 振 幅 8.28%
- 歷史最低 0.9897
- 每 手 1
- 風險率 0.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MacroGenics’ MGC026 Study: A New Hope for Advanced Solid Tumors?
MacroGenics Inc (($MGNX)) announced an update on their ongoing clinical study. ...
08-15 00:27
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
MacroGenics reported Q2 2025 financial results with a cash position of $176.5M, up from $134.9M in Q2 2024, and highlighted strategic priorities for lorigerlimab, MGC026/MGC028 advancement, IND submissions, and partnerships. Notably, they received a $70M upfront payment from Sagard for ZYNYZ and aim to enhance operational efficiency to improve financial position.
08-14 20:01
MacroGenics appoints new CEO
MacroGenics (NASDAQ:MGNX) has appointed Eric Risser as president, chief executive officer, and board member effective August 13, 2025. Risser has served as the company's chief operating officer since ...
08-14 04:24
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
MacroGenics announces Eric Risser as new President, CEO, and Board member, succeeding Scott Koenig after 24 years of leadership. Risser, who has been COO since 2022, brings nearly 30 years of biotech experience and has helped raise over $1.6 billion in capital. The company looks to build on its success in developing cancer therapies under Risser's leadership.
08-13 20:01
映恩生物的五年，资本很满意。。。
（来源：成长企业常识） 后浪森林研究室 | 罗可 编辑 | 许佳维 映恩生物从2020年创立只有五年时间，布局了12款ADC管线，不仅在快速...
08-11 07:58
MacroGenics’ Prostate Cancer Study: A Potential Game-Changer?
MacroGenics Inc (($MGNX)) announced an update on their ongoing clinical study. ...
08-01 00:23
MacroGenics’ Promising Study on Advanced Solid Tumors: Key Insights for Investors
MacroGenics Inc (($MGNX)) announced an update on their ongoing clinical study. ...
07-29 00:08
新浪财经ESG：MacroGenics Inc. MSCI（明晟）ESG评级调升至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-27 07:00
Incyte reports results from blood disorder studies
Incyte (NASDAQ:INCY) reported early results from two studies on INCA033989, a new targeted antibody aimed at patients with blood disorders linked to mutant calreticulin. In these studies, 86% of high-...
06-17 01:23
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
MacroGenics received a $70 million upfront payment from Sagard Healthcare Partners through a royalty purchase agreement for ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor. This transaction extends MacroGenics' cash runway through the first half of 2027. ZYNYZ is developed for treating certain cancers and is marketed by Incyte in the U.S. The agreement allows Sagard to receive capped royalty interests on global net sales, with MacroGenics resuming ro...
06-10 11:00
